00460 SIHUAN PHARM
- 0.560
- +0.020+3.70%
SIHUAN PHARM News
四環醫藥：2023年度報告
Sihuan Pharmaceutical (00460.HK): Three Mendon insulin series products developed by Huisheng Biotech have obtained the proposed selection criteria in the special continuous procurement of insulin
Gelonghui, April 25, 丨 Sihuan Pharmaceutical (00460.HK) announced that on April 23, 2024, Huisheng Biopharmaceutical Co., Ltd., a non-wholly-owned subsidiary of the Group, participated in the national centralized drug procurement (insulin special continuation) declaration work organized by the State Organization Drug Joint Procurement Office. The three products developed by Huisheng Biotech, Mendon Insulin 30 Injection, and Menton Insulin 50 Injection were eligible for selection in this special succession of insulin purchases, and they all plan to select Class A varieties. The current centralized insulin procurement cycle starts from the date of implementation of the selection results to 2027
Sihuan Pharmaceutical (0460.HK): Two-wheel drive for medical aesthetics and innovative pharmaceuticals, “high valuation flexibility+high growth new business” creates the company's alpha
Against the backdrop of a weak economic environment in 2023, the medical and aesthetic industry showed a strong growth momentum. The latest financial data from the Hong Kong stock Sihuan Pharmaceutical also confirms this. In 2023, Sihuan Pharmaceutical's medical and aesthetic business revenue both achieved high growth, with revenue of 450 million yuan, up 200% year on year, and segment profit of 90 million yuan, up 2450% year on year.
Sihuan Pharmaceutical (00460): Strong medical and aesthetic performance explodes, profit inflection point upward, leveraging valuation logic
Sihuan Pharmaceutical's dual growth logic continues to be interpreted.
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments
Sihuan Pharmaceutical (HKG:0460) narrowed its 2023 loss attributable to owners to 54.0 million yuan, or 0.0058 yuan per share, from 1.91 billion yuan, from 0.2090 yuan per share, the previous year. Th
The Three-year Earnings Decline Has Likely Contributed ToSihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders Losses of 69% Over That Period
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term Sihuan Pharmaceutical Holdings Group Ltd. (HK
Sihuan Pharmaceutical (00460) announced its 2023 annual results, with total revenue reaching 1,860.5 billion yuan. The revenue of the medical and aesthetic division increased by about 200.3% year-on-year
According to Zhitong Finance App News, Sihuan Pharmaceutical (00460) released its annual results for the year ended December 31, 2023, with total revenue of approximately RMB 1,8605 million; of these, revenue from medical and aesthetic products was RMB 449.9 billion, up about 200.3% year on year, mainly due to the full liberalization of domestic epidemic control and the gradual recovery of consumer demand, the Group's medical and aesthetic platform Qianyan Space achieved phased success through channel inventory cleaning, strategic cooperation with many medical and aesthetic institutions, and vigorously promoted the 3.0 version upgrade of the marketing strategy. Successfully achieved medical and aesthetic sales revenue
SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China
Sihuan Pharmaceutical Holdings (HKG:0460) received a class III medical device registration certificate for Sylfirm X from the National Medical Products Administration of China, according to a filing w
Sylfirm X, a dual-wave radiofrequency therapy device exclusively represented by Sihuan Pharmaceutical (00460.HK), was issued a registration certificate for three types of medical devices by the State Drug Administration
GLONGHUI March 25 丨 Sihuan Pharmaceutical (00460.HK) announced that it is the exclusive agent of the Group and is managed by Korea's Vio Co., Ltd. (Viol.co. , Ltd.) The dual-wave radiofrequency therapy device Sylfirm X (the “Product”) manufactured by (“Vio Korea”) officially obtained a Class III medical device registration certificate issued by China's State Drug Administration on March 19, 2024. Sylfirm X is the world's first dual-wave radiofrequency treatment device approved by the US Food and Drug Administration (FDA) and the National Drug Administration. It emits high-frequency electric current to promote skin tissue coagulation, which can effectively reduce skin wrinkles
Sihuan Pharmaceutical (00460.HK) plans to hold a board meeting on March 28 to approve the annual results
GLONGHUI March 18 | Sihuan Pharmaceutical (00460.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to approve (among other things) the results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider paying a final dividend (if any).
四環醫藥：董事會會議通知
Germany to Approve Cannabis Bill This Week in Legalization Drive
German lawmakers will approve delayed legislation decriminalizing personal use of cannabis this week, paving the way for it to take effect on April 1, according to Health Minister Karl Lauterbach.
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring
Sihuan Pharmaceutical Holdings (HKG:0460) unit Longyu Hongda Investment Management formed a consortium with other parties for the restructuring of Ji Yao Holding (SHE:300108) following its bankruptcy
Sihuan Pharmaceutical (00460.HK): Participating in the pre-restructuring investors selected for the bankruptcy and restructuring project of Ji Pharmaceutical Holdings
Gelonghui, Feb. 7 | Sihuan Pharmaceutical (00460.HK) announced that the Tonghua Intermediate People's Court of Jilin Province issued a decision to Jiyao Holding Group Co., Ltd. on November 27, 2023, deciding to initiate pre-restructuring procedures against Ji Yao Holdings and appoint a temporary manager to carry out related work during the pre-restructuring period. Subsequently, Jiyao Holdings issued an announcement to publicly recruit investors for the restructuring. Longyu Hongda Investment Management Co., Ltd., a subsidiary of the company, formed a consortium with other industrial and financial investors to sign up to participate in the bankruptcy and restructuring project of Ji Pharmaceutical Holdings. The consortium was recently notified by the temporary manager of Ji Pharmaceutical Holdings
Changes in Hong Kong stocks | Sihuan Pharmaceutical (00460) rose 10%, and the new class 1 diabetes drug gagliflozin was previously approved for listing
Sihuan Pharmaceutical (00460) rose 10%. As of press release, it was up 10% to HK$0.55, with a turnover of HK$3.9036 million.
Sihuan Pharmaceutical (00460) fell 2.00% and now reports 0.500 yuan, hitting a 52-week low
As of 16:08, Sihuan Pharmaceutical (00460) fell 2.00% from yesterday's closing price and is now reporting a 52-week low of $0.500; the trading volume was 10.276,900 shares, with a turnover of HK$5.135,500.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Changes in Hong Kong stocks | Sihuan Pharmaceutical (00460) rose more than 5%, and a new subsidiary drug to treat diabetes was approved for listing by the State Drug Administration
Sihuan Pharmaceutical (00460) rose more than 5%. As of press release, it rose 5.36% to HK$0.59, with a turnover of HK$3,532 million.
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug
China's medical products administrator granted drug registration approval to Sihuan Pharmaceutical Holdings Group (HKG:0460) subsidiary Huisheng Biopharmaceutical for the Proline Janagliflozin tablets
Analysis
Price Target
No Data
